CD73: An emerging checkpoint for cancer immunotherapy

Siqi Chen, Derek Alan Wainwright, Jennifer D. Wu, Yong Wan, Daniela E. Matei, Yi Zhang, Bin Zhang

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations


CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.

Original languageEnglish (US)
Pages (from-to)983-997
Number of pages15
Issue number11
StatePublished - 2019


  • CD73
  • adenosine receptor
  • immune checkpoint blockade
  • immunotherapy
  • tumor evasion

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'CD73: An emerging checkpoint for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this